FDA approves Takeda narcolepsy drug, signaling a new era for orexin-based therapies
TL;DR Summary
The FDA approved Takeda’s Orzeyful, a twice-daily orexin receptor agonist for narcolepsy type 1, a first-in-class treatment that improved daytime wakefulness and reduced sleepiness in Phase 3 trials, offering potential benefits over current therapies and hinting at broader neurological applications, though long-term safety and applicability remain under study.
- Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments STAT
- US FDA approves Takeda's sleep disorder pill Reuters
- Yomiuri: Japan Set to Approve Drug that Treats Narcolepsy MarketWatch
- Orexin receptor agonists set to propel narcolepsy treatment into a new era Pharmaceutical Technology
- FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1 HCPLive
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
2 min
vs 3 min read
Condensed
91%
512 → 48 words
Want the full story? Read the original article
Read on STAT